The emerging agenda of stratified medicine in neurology

Nature Reviews Neurology

Volumn 10, Issue 1, 2014, Pages 15-26

  Matthews, Paul M ^a   Edison, Paul ^a   Geraghty, Olivia C ^b   Johnson, Michael R ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTICONVULSIVE AGENT; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CARBAMAZEPINE; HLA A ANTIGEN; HLA B ANTIGEN; PHENYTOIN; PRESENILIN 1; PRESENILIN 2; WARFARIN;

ADVERSE OUTCOME; ALZHEIMER DISEASE; ANTICOAGULANT THERAPY; APOE4 GENE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; EPILEPSY; EXOME; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HIGH RISK PATIENT; HLA A GENE; HLA B GENE; HUMAN; MEDICINE; MULTIPLE SCLEROSIS; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PSEN1 GENE; PSEN2 GENE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEVENS JOHNSON SYNDROME; STRATIFICATION; STRATIFIED MEDICINE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

COST-BENEFIT ANALYSIS; HUMANS; INDIVIDUALIZED MEDICINE; NERVOUS SYSTEM DISEASES; NEUROLOGY; PROGNOSIS;

EID: 84891830807     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.245     Document Type: Review

References (130)

1. Trusheim, M. R., Berndt, E. R. & Douglas, F. L. Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6, 287-293 (2007
2. Horwitz, R. I., Cullen, M. R., Abell, J. & Christian, J. B. (De)personalized medicine. Science 339, 1155-1156 (2013
3. Schilsky, R. L. Personalized medicine in oncology: The future is now. Nat. Rev. Drug Discov. 9, 363-366 (2010
4. Saver, J. L. et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3 to 4.5-hour window: Joint outcome table analysis of the ECASS 3 trial. Stroke 40, 2433-2437 (2009
5. Costa, J. et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: A systematic review and meta-analysis. Epilepsia 52, 1280-1291 (2011
6. Romero, J. R. Prevention of ischemic stroke: Overview of traditional risk factors. Curr. Drug Targets 8, 794-801 (2007
7. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis (North American Symptomatic Carotid Endarterectomy Trial Collaborators). N. Engl. J. Med. 325, 445-453 (1991
8. [No authors listed] Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273, 1421-1428 (1995
9. Sitzer, M. et al. Plaque ulceration and lumen thrombus are the main sources of cerebral microemboli in high-grade internal carotid artery stenosis. Stroke 26, 1231-1233 (1995
10. Johnston, S. C. et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369, 283-292 (2007
11. Gage, B. F. et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001
12. Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 137, 263-272 (2010
13. Pisters, R. et al. A novel user-friendly score (HAS-BLED) to assess 1 year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 138, 1093-1100 (2010
14. Carlquist, J. F. & Anderson, J. L. Using pharmacogenetics in real time to guide warfarin initiation: A clinician update. Circulation 124, 2554-2559 (2011
15. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00839657?term=NCT+00839657&rank=1 (2013
16. Lou, M. et al. The HAT Score: A simple grading scale for predicting hemorrhage after thrombolysis. Neurology 71, 1417-1423 (2008
17. Cucchiara, B., Tanne, D., Levine, S. R., Demchuk, A. M. & Kasner, S. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 17, 331-333 (2008
18. Strbian, D. et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: The DRAGON score. Neurology 78, 427-432 (2012
19. Stroke Outcomes Research Canada. Ischemic Stroke Predictive Risk Score [online], http://www.sorcan.ca/iscore (2012
20. Chung, W. H. & Hung, S. I. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. J. Dermatol. Sci. 66, 190-196 (2012
21. Ferrell, P. B. Jr & McLeod, H. L. Carbamazepine, HLA B.1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9, 1543-1546 (2008
22. Yip, V. L., Marson, A. G., Jorgensen, A. L., Pirmohamed, M. & Alfirevic, A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review. Clin. Pharmacol. Ther. 92, 757-765 (2012
23. Hung, S. I. et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11, 349-356 (2010
24. US Department of Health and Human Services. Information for healthcare professionals: Dangerous or even fatal skin reactions - carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). US Food and Drug Administration [online], http://www.fda.gov/Drugs/DrugSafety/ PostmarketdrugsafetyinformationforPatientsandProviders/ucm124718.htm (2007
25. Medicines and Healthcare Products Regulators Agency. Carbamazepine: Genetic testing recommended in some Asian populations. Medicines and Healthcare Products Regulators Agency [online], http://www.mhra.gov.uk/Safetyinformation/ DrugSafetyUpdate/CON084888 (2008
26. Dong, D., Sung, C. & Finkelstein, E. A. Cost-effectiveness of HLA B.1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 79, 1259-1267 (2012
27. Hung, S. I. & Chung, W. H. Cost-effectiveness of HLA B 1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 80, 1621 (2013
28. Ozeki, T. et al. Genome-wide association study identifies HLA A 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034-1041 (2011
29. McCormack, M. et al. HLA A. 3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011
30. Franciotta, D., Kwan, P. & Perucca, E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr. Opin. Neurol. 22, 144-149 (2009
31. Johnson, M. R., Tan, N. C., Kwan, P. & Brodie, M. J. Newly diagnosed epilepsy and pharmacogenomics research: A step in the right direction? Epilepsy Behav. 22, 3-8 (2011
32. Chan, A., Pirmohamed, M. & Comabella, M. Pharmacogenomics in neurology: Current state and future steps. Ann. Neurol. 70, 684-697 (2011
33. Kwan, P. & Brodie, M. J. Early identification of refractory epilepsy. N. Engl. J. Med. 342, 314-319 (2000
34. Johnson, M. R. et al. A twin study of genetic influences on epilepsy outcome. Twin Res. 6, 140-146 (2003
35. Speed, D. A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy. Hum. Mol. Genet. http://dx.doi.org/10.1093/hmg/ddt403
36. De Jonghe, P. Molecular genetics of Dravet syndrome. Dev. Med. Child Neurol. 53 (Suppl. 2), 7-10 (2011
37. Epi, K. C. et al. De novo mutations in epileptic encephalopathies. Nature 501, 217-221 (2013
38. Weinshenker, B. G. et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 112, 133-146 (1989
39. Derfuss, T. Personalized medicine in multiple sclerosis: Hope or reality? BMC Med. 10, 116 (2012
40. Miller, A., Avidan, N., Tzunz-Henig, N. & Glass-Marmor, L. Translation towards personalized medicine in multiple sclerosis. J. Neurol. Sci. 274, 68-75 (2008
41. Sormani, M. P. & De Stefano, N. Defining and scoring response to IFN-ß. Nat. Rev. Neurol. 9, 504-512 (2013
42. Rio, J., Comabella, M. & Montalban, X. Predicting responders to therapies for multiple sclerosis. Nat. Rev. Neurol. 5, 553-560 (2009
43. Koch, M. W., Metz, L. M., Agrawal, S. M. & Yong, V. W. Environmental factors and their regulation of immunity in multiple sclerosis. J. Neurol. Sci. 324, 10-16 (2013
44. Ramagopalan, S. V. et al. Association of smoking with risk of multiple sclerosis: A population-based study. J. Neurol. 260, 1778-1781 (2013
45. Montalban, X. et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74, 427-434 (2010
46. Sormani, M. P., Rovaris, M., Comi, G. & Filippi, M. A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology 73, 1538-1542 (2009
47. Bielekova, B. et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 65, 1071-1076 (2005
48. Rovaris, M. et al. Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: A large-scale, multicentre study. Mult. Scler. 17, 319-326 (2011
49. Fisniku, L. K. et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131, 808-817 (2008
50. Sormani, M. P. et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Ann. Neurol. 65, 268-275 (2009
51. Sormani, M. P., Arnold, D. L. & De Stefano, N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann. Neurol. http://dx.doi.org/10.1002/ana.24018
52. Owen, D. R. & Matthews, P. M. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. Int. Rev. Neurobiol. 101, 19-39 (2011
53. Politis, M. et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 79, 523-530 (2012
54. Farrell, R. A. et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73, 32-38 (2009
55. Lunemann, J. D. et al. Elevated Epstein-Barr virus-encoded nuclear antigen 1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 67, 159-169 (2010
56. Wandinger, K. et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 55, 178-184 (2000
57. Ascherio, A. & Marrie, R. A. Vitamin D in MS: A vitamin for 4 seasons. Neurology 79, 208-210 (2012
58. Kebir, H. et al. Preferential recruitment of interferon-?-expressing TH17 cells in multiple sclerosis. Ann. Neurol. 66, 390-402 (2009
59. Bushnell, S. E. et al. Serum IL 17F does not predict poor response to IM IFNß-1a in relapsing-remitting MS. Neurology 79, 531-537 (2012
60. Avolio, C. et al. Serum MMP 9/TIMP 1 and MMP 2/TIMP 2 ratios in multiple sclerosis: Relationships with different magnetic resonance imaging measures of disease activity during IFN ß 1a treatment. Mult. Scler. 11, 441-446 (2005
61. Villar, L. M. et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol. 53, 222-226 (2003
62. Khademi, M. et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult. Scler. 17, 335-343 (2011
63. Comabella, M. et al. Plasma osteopontin levels in multiple sclerosis. J. Neuroimmunol. 158, 231-239 (2005
64. Axelsson, M. et al. Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis. J. Neurol. 258, 882-888 (2011
65. Gunnarsson, M. et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann. Neurol. 69, 83-89 (2011
66. Norgren, N. et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63, 1586-1590 (2004
67. Grossman, I. et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet. Genomics 17, 657-666 (2007
68. Hesse, D., Sellebjerg, F. & Sorensen, P. S. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 73, 372-377 (2009
69. Fainardi, E. et al. Presence of detectable levels of soluble HLA G molecules in CSF of relapsing-remitting multiple sclerosis: Relationship with CSF soluble HLA I and IL 10 concentrations and MRI findings. J. Neuroimmunol. 142, 149-158 (2003
70. Polman, C. H. et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 9, 740-750 (2010
71. Goodin, D. S. et al. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68, 977-984 (2007
72. Baranzini, S. E. et al. Transcription-based prediction of response to IFNß using supervised computational methods. PLoS Biol. 3, e2 (2005
73. Baarsen, L. G. & Baarsen, V. Pharmacogenomics of IFN ß in multiple sclerosis: Towards a personalized medicine approach. Pharmacogenomics 10, 97-108 (2009
74. Sturzebecher, S. et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126, 1419-1429 (2003
75. Cribbs, D. H. et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: A microarray study. J. Neuroinflammation 9, 179 (2012
76. Jones, J. L. et al. IL 21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119, 2052-2061 (2009
77. Feldman, H. H. et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 178, 825-836 (2008
78. Jack, C. R. Jr et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 257-262 (2011
79. Kantarci, K. et al. Magnetic resonance spectroscopy, beta-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology 77, 951-958 (2011
80. Nordberg, A., Rinne, J. O., Kadir, A. & Langstrom, B. The use of PET in Alzheimer disease. Nat. Rev. Neurol. 6, 78-87 (2010
81. Weiner, M. W. et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 8, S1-S68 (2012
82. Pike, K. E. et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia 49, 2384-2390 (2011
83. Nussbaum, R. L. Genome-wide association studies, Alzheimer disease, and understudied populations. JAMA 309, 1527-1528 (2013
84. Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. http://dx.doi.org/10.1038/ng.2802
85. Goate, A. & Hardy, J. Twenty years of Alzheimer's disease-causing mutations. J. Neurochem. 120 (Suppl. 1), 3-8 (2012
86. Sanan, D. A. et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94, 860-869 (1994
87. Weisgraber, K. H. & Mahley, R. W. Human apolipoprotein E: The Alzheimer's disease connection. FASEB J. 10, 1485-1494 (1996
88. Toledo, J. B. et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 136, 2697-2706 (2013
89. Harold, D. et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41, 1088-1093 (2009
90. Hollingworth, P. et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429-435 (2011
91. Critical Path Institute. Alzheimer's Disease Clinical Trial Simulation Tool. Critical Path Institute [online], http://c-path.org/programs/camd/ simulation-tool
92. Klunk, W. E. et al. The binding of 2 (4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 23, 2086-2092 (2003
93. Klunk, W. E. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol. Aging 32 (Suppl. 1), S20-S36 (2011
94. Edison, P. et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology 68, 501-508 (2007
95. Pike, K. E. et al. ß-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844 (2007
96. Jack, C. R. Jr et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216 (2013
97. Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aß42 in humans. Ann. Neurol. 59, 512-519 (2006
98. Buerger, K. et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041 (2006
99. Hampel, H. et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 95, 579-593 (2011
100. Whitwell, J. L. et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: A case-control study. Lancet Neurol. 11, 868-877 (2012
101. Ryan, N. S. & Fox, N. C. Imaging biomarkers in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1180, 20-27 (2009
102. Douaud, G. et al. Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease. J. Neurosci. 33, 2147-2155 (2013
103. Landau, S. M. et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 32, 1207-1218 (2011
104. Landau, S. M. et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238 (2010
105. Sabate, E. Adherence to long-term therapies. Evidence for action (World Health Organisation, 2003
106. Hamburg, M. A. & Collins, F. S. The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010
107. Hobart, J. C., Cano, S. J., Zajicek, J. P. & Thompson, A. J. Rating scales as outcome measures for clinical trials in neurology: Problems, solutions, and recommendations. Lancet Neurol. 6, 1094-1105 (2007
108. Bristol-Myers Squibb Company. Full prescribing information: Coumadin (warfarin sodium) (Bristol-Myers Squibb, 2011
109. Marburger, J. H. & Kvamme, E. F. Report of the President's Council of Advisors on Science and Technology (ed. US President's Council of Advisors on Science and Technology (PCOST); Washington, 2008
110. Committee on a Framework for Development of a New Taxonomy of Disease; National Research Council. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease (The National Academies Press, 2013
111. Hood, L. & Friend, S. H. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol. 8, 184-187 (2011
112. Puetz, V., Dzialowski, I., Hill, M. D. & Demchuk, A. M. The Alberta Stroke Program Early CT Score in clinical practice: What have we learned? Stroke 4, 354-364 (2009
113. Bermel, R. A. et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann. Neurol. 73, 95-103 (2013
114. Wei, X. et al. Targeted next-generation sequencing as a comprehensive test for patients with and female carriers of DMD/BMD: A multi-population diagnostic study. Eur. J. Hum. Genet. http://dx.doi.org/10.1038/ejhg.2013.82
115. Vasli, N. et al. Next generation sequencing for molecular diagnosis of neuromuscular diseases. Acta Neuropathol. 124, 273-283 (2012
116. Vasli, N. & Laporte, J. Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders. Acta Neuropathol. 125, 173-185 (2013
117. Dziubianau, M. et al. TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. Am. J. Transplant. http://dx.doi.org/10.1111/ajt.12431
118. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: A revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57-63 (2009
119. Marrie, R. A. et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 72, 117-124 (2009
120. Marrie, R. A. et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 74, 1041-1047 (2010
121. Banerjee, A. K. & Ingate, S. Web-based patient-reported outcomes in drug safety and risk management: Challenges and opportunities? Drug Saf. 35, 437-446 (2012
122. Willke, R. J., Burke, L. B. & Erickson, P. Measuring treatment impact: A review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control. Clin. Trials 25, 535-552 (2004
123. van Ommen, G. J., van Deutekom, J. & Aartsma-Rus, A. The therapeutic potential of antisense-mediated exon skipping. Curr. Opin. Mol. Ther. 10, 140-149 (2008
124. Nakamura, A. & Takeda, S. Exon-skipping therapy for Duchenne muscular dystrophy. Lancet 378, 546-547 (2011
125. Kanagawa, M. & Toda, T. The genetic and molecular basis of muscular dystrophy: Roles of cell-matrix linkage in the pathogenesis. J. Hum. Genet. 51, 915-926 (2006
126. Mitrpant, C., Fletcher, S. & Wilton, S. D. Personalised genetic intervention for Duchenne muscular dystrophy: Antisense oligomers and exon skipping. Curr. Mol. Pharmacol. 2, 110-121 (2009
127. Cox, T. M. & Cachon-Gonzalez, M. B. The cellular pathology of lysosomal diseases. J. Pathol. 226, 241-254 (2012
128. Suzuki, Y. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease. Brain Dev. 35, 515-523 (2013
129. Germain, D. P. et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: Report from two phase 2 clinical studies. Orphanet J. Rare Dis. 7, 91 (2012
130. Davis, J. C. et al. The microeconomics of personalized medicine: Today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 8, 279-286 (2009